Biocon to take on Roche Pharma with its psoriasis drug to treat moderate to severe Covid patients
The company is marketing the drug as a replacement to Roche’s tocilizumab (originally approved for rheumatoid arthritis) that is currently in off-label use among Covid-19 patients who suffer from cytokine release syndrome (CRS).
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news
More News: Actemra | Arthritis | Biotechnology | COVID-19 | Marketing | Pharmaceuticals | Psoriasis | Rheumatoid Arthritis | Rheumatology